Paris (France), March 17, 2025 – PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology, announced that the U.S. Food and Drug ...

Paris (France), April 25, 2024 – PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology, and Institut Curie, France’s leading cancer ...

PARIS--(BUSINESS WIRE)--PEP-Therapy, a biotechnology company developing targeted therapies for cancer treatments, has raised €1.3 million in initial funding. This sum, invested by the Quadrivium 1 ...

Additional funding comprises €1.6 million in equity as well as a €1 million loan from Bpifrance PEP-Therapy will use the funds to finance the Phase I a/b clinical trial of PEP-010, PEP-Therapy's lead ...

PARIS, March 16, 2021 /PRNewswire/ -- PEP-Therapy, a biotechnology company developing cell penetrating peptides as targeted therapies in oncology, and Institut Curie, France's leading cancer center, ...

PARIS, April 22, 2021 /PRNewswire/ -- PEP-Therapy, a biotechnology company developing cell penetrating peptides as targeted therapies for the treatment of cancers, announces it has raised a €2.75 ...

PEP-Therapy and Institut Curie announce first patients dosed in Phase I clinical trial of PEP-010 for the treatment of advanced solid tumors Paris (France), 5 th October 2021 – PEP-Therapy, a clinical ...

Smiths Medical, a leading medical device manufacturer, today announces the launch of the acapella (R) choice blue vibratory PEP therapy system. Acapella (R) is designed to aid in the removal of ...